Ombrabulin

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP07754CAS No. ：181816-48-8Purity：98%

Get Quotation Now

Tel: 0086-13026320035 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	181816-48-8	Cat. No.	BCP07754
Name	Ombrabulin
Synonyms	AVE-8062; AVE 8062; AVE8062;
SMILES
Chemical Name
Formula	C21H26N2O6	M. Wt	402.44
Purity	98%	Storage	Store at 4-8°C
Description	Ombrabulin is a synthetic water-soluble analogue of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular-disrupting and antineoplastic activities. Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis. Ombrabulin was discovered by Ajinomoto and under development by Sanofi-Aventis. It is currently in Phase III clinical trials for the treatment of advanced-stage soft-tissue sarcoma. Ombrabulin was granted orphan drug status by the European Medicines Agency in April 2011. Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth.